



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

September 7, 2026

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs / Madam,

Sub: Outcome of Board Meeting – Discontinuation of Minipress XL.

Ref.: Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you the outcome of the meeting of Board of Directors of the Company held today, i.e., September 7, 2026, that commenced at 10.33 a.m. and concluded at 11.03 a.m. as under:

Pfizer Limited (“the Company”) will discontinue the marketing, distribution and sale of Minipress XL with effect from September 7, 2026. This is consequent to a decision by Pfizer Inc. USA. to discontinue the manufacture of Minipress XL.

In connection with the above, the Company will receive a lump sum payment of USD 13.9 Million (~Rs. 131.38 Crore) from Pfizer Inc. USA.

Request you to please take the above on record.

Thanking you,

Yours truly,
For **Pfizer Limited**

Prajeet Nair
Director – Corporate Services & Company Secretary